EUVIMEDEUVIMED entdecken
Crossref

Magnetic-optical dual-modality imaging monitoring chemotherapy efficacy of pancreatic ductal adenocarcinoma with a low-dose fibronectin-targeting Gd-based contrast agent

Wenjia Zhang, Xiaolong Liang, Xinyu Zhang, Wei Tong, Guangyuan Shi, Haozhuo Guo, Zhengyu Jin, Jie Tian iD, Yang Du, Huadan Xue

European Journal of Nuclear Medicine and Molecular Imaging · 2024

DOI: 10.1007/s00259-024-06617-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2024. Verfasst von Wenjia Zhang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College, Peking Union Medical College Hospita…. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Contrast Media, Magnetic Resonance Imaging, Pancreatic Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Beijing Natural Science Foundation, National High Level Hospital Clinical Research Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Pancreatic ductal adenocarcinoma (PDAC) is a lethal hypovascular tumor surrounded by dense fibrosis. Albumin-bound paclitaxel and gemcitabine (AG) chemotherapy is the mainstay of PDAC treatment through depleting peritumoral fibrosis and killing tumor cells; however, it remains challenging due to the lack of a noninvasive imaging method evaluating fibrotic changes during AG chemotherapy. In this study, we developed a dual-modality imaging platform that enables noninvasive, dynamic, and quantitative assessment of chemotherapy-induced fibrotic changes through near-infrared fluorescence molecular imaging (FMI) and magnetic resonance imaging (MRI) using an extradomain B fibronectin (EDB-FN)-targeted imaging probe (ZD2-Gd-DOTA-Cy7). METHODS: The ZD2-Gd-DOTA-Cy7 probe was constructed by conjugating a peptide (Cys-TVRTSAD) to Gd-DOTA and the near-infrared dye Cy7. PDAC murine xenograft models were intravenously injected with ZD2-Gd-DOTA-Cy7 at a Gd concentration of 0.05 mmol/kg or free Cy7 and Gd-DOTA as control. The normalized tumor background ratio (TBR) on FMI and the T1 reduction ratio on MRI were quantitatively analyzed. For models receiving AG chemotherapy or saline, MRI/FMI was performed before and after treatment. Histological analyses were performed for validation. RESULTS: The ZD2-Gd-DOTA-Cy7 concentration showed a linear correlation with the fluorescence intensity and T1 relaxation time in vitro. The optimal imaging time was 30 min after injection of the ZD2-Gd-DOTA-Cy7 (0.05 mmol/kg), only half of the clinic dosage of gadolinium. Additionally, ZD2-Gd-DOTA-Cy7 generated a 1.44-fold and 1.90-fold robust contrast enhancement compared with Cy7 (P < 0.05) and Gd-DOTA (P < 0.05), respectively. For AG chemotherapy monitoring, the T1 reduction ratio and normalized TBR in the fibrotic tumor areas were significantly increased by 1.99-fold (P < 0.05) and 1.78-fold (P < 0.05), respectively, in the control group compared with those in the AG group. CONCLUSION: MRI/FMI with a low dose of ZD2-Gd-DOTA-Cy7 enables sensitive imaging of PDAC and the quantitative assessment of fibrotic changes during AG chemotherapy, which shows potential clinical applications for precise diagnosis, post-treatment monitoring, and disease management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalContrast MediaMagnetic Resonance ImagingPancreatic NeoplasmsFibronectinsAnimalsMiceHumansCell Line, TumorMultimodal ImagingOptical ImagingOrganometallic CompoundsTreatment OutcomeGemcitabineGadoliniumFemaleDeoxycytidineHeterocyclic Compounds

Stichwörter der Autor:innen

FibronectinFluorescence molecular imagingMagnetic resonance imagingMolecular imagingPancreatic cancer

Substanzen

Contrast Mediagadolinium 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetateFibronectinsOrganometallic CompoundsGemcitabineGadoliniumDeoxycytidineHeterocyclic Compounds

Autor:innen und Institutionen

  • Department of Radiology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Beijing, 10…
  • Department of Radiology, Peking University People's Hospital, Beijing, 100032, China.
  • CAS Key Laboratory of Molecular Imaging, Beijing Key Laboratory of Molecular Imaging, the State Key Laboratory of Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, No. 95…
  • Department of Ultrasound, Peking University Third Hospital, Beijing, 100191, China.
  • Beijing Advanced Innovation Centre for Big Data-Based Precision Medicine, School of Medicine, Beihang University, Beijing, 100191, China. jie.tian@ia.ac.cn.
  • The University of Chinese Academy of Sciences, Beijing, 100049, China. yang.du@ia.ac.cn.

ORCID-Profile: Jie Tian

Förderung

  • National Natural Science Foundation of China
  • Beijing Natural Science Foundation
  • National High Level Hospital Clinical Research Funding
  • Peking University Third Hospital

Zitieren

APA

Zhang, W., Liang, X., Zhang, X., Tong, W., Shi, G., Guo, H., Jin, Z., Tian, J., Du, Y., & Xue, H. (2024). Magnetic-optical dual-modality imaging monitoring chemotherapy efficacy of pancreatic ductal adenocarcinoma with a low-dose fibronectin-targeting Gd-based contrast agent. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06617-w

Vancouver

Zhang W, Liang X, Zhang X, Tong W, Shi G, Guo H, et al. Magnetic-optical dual-modality imaging monitoring chemotherapy efficacy of pancreatic ductal adenocarcinoma with a low-dose fibronectin-targeting Gd-based contrast agent. European Journal of Nuclear Medicine and Molecular Imaging. 2024. doi:10.1007/s00259-024-06617-w

BibTeX
@article{Zhang2024,
  author = {Zhang, Wenjia and Liang, Xiaolong and Zhang, Xinyu and Tong, Wei and Shi, Guangyuan and Guo, Haozhuo and Jin, Zhengyu and Tian, Jie and Du, Yang and Xue, Huadan},
  title = {Magnetic-optical dual-modality imaging monitoring chemotherapy efficacy of pancreatic ductal adenocarcinoma with a low-dose fibronectin-targeting Gd-based contrast agent},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2024},
  doi = {10.1007/s00259-024-06617-w}
}
Kostenlos starten →